Advanced search
Publication Cover
Bioengineered Volume 11, 2020 - Issue 1
Submit an article Journal homepage
901
Views
3
CrossRef citations to date
0
Altmetric
Research Paper

Clinical significance of eukaryotic translation initiation factor 5A2 in papillary thyroid cancer

Hongmei Zhanga Department of Surgical Day Ward, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
,
Kejun Zhangb Department of Thyroid Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0370-1462
ORCID Icon,
Liang Ningb Department of Thyroid Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
,
Dong Chenc Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, ChinaORCID Iconhttps://orcid.org/0000-0001-6766-2787
ORCID Icon,
Fengyun Haoc Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
&
Peng Lid Department of Endocrinology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, ChinaCorrespondence[email protected]
Pages 1325-1333 | Received 31 Aug 2020, Accepted 06 Nov 2020, Published online: 29 Nov 2020

References

  • Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 1993;328(8):553–559.
  • Ito Y, Higashiyama T, Takamura Y, et al. Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg. 2007;31(11):2085–2091.
  • D’Cruz AK, Vaish R, Vaidya A, et al. Molecular markers in well-differentiated thyroid cancer. Eur Arch Otorhinolaryngol. 2018;275(6):1375–1384.
  • Guan H, Toraldo G, Cerda S, et al. Utilities of RAS mutations in preoperative fine needle biopsies for decision making for thyroid nodule management: results from a single-center prospective cohort. Thyroid. 2020;30(4):536–547.
  • Lee MY, Ku BM, Kim HS, et al. Genetic alterations and their clinical implications in high-recurrence risk papillary thyroid cancer. Cancer Res Treat. 2017;49(4):906–914.
  • Razavi SA, Modarressi MH, Yaghmaei P, et al. Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers? Endocrine. 2017;57(3):428–435.
  • Ali KM, Awny S, Ibrahim DA, et al. Role of P53, E-cadherin and BRAF as predictors of regional nodal recurrence for papillary thyroid cancer. Ann Diagn Pathol. 2019;40:59–65.
  • Liu R, Xing M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016;23(3):R143–55.
  • Estrada-Flórez AP, Bohórquez ME, Vélez A, et al. BRAF and TERT mutations in papillary thyroid cancer patients of Latino ancestry. Endocr Connect. 2019;8(9):1310–1317.
  • Rossi M, Buratto M, Tagliati F, et al. Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer. Thyroid. 2015;25(2):221–228.
  • Markham A, Keam SJ. Selumetinib: first approval. Drugs. 2020;80(9):931–937.
  • Kim KB, Cabanillas ME, Lazar AJ, et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid. 2013;23(10):1277–1283.
  • Park MH, Nishimura K, Zanelli CF, et al. Functional significance of eIF5A and its hypusine modification in eukaryotes. Amino Acids. 2010;38(2):491–500.
  • Mathews MB, Hershey JW. The translation factor eIF5A and human cancer. Biochim Biophys Acta. 2015;1849(7):836–844.
  • Caraglia M, Park MH, Wolff EC, et al. eIF5A isoforms and cancer: two brothers for two functions? Amino Acids. 2013;44(1):103–109.
  • Fujimura K, Choi S, Wyse M, et al. Eukaryotic translation initiation factor 5A (EIF5A) regulates pancreatic cancer metastasis by modulating RhoA and Rho-associated kinase (ROCK) protein expression levels. J Biol Chem. 2015;290(50):29907–29919.
  • Tang DJ, Dong SS, Ma NF, et al. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology. 2010;51(4):1255–1263.
  • Fujimura K, Wright T, Strnadel J. A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer. Cancer Res. 2014;74(22):6671–6681.
  • Zender L, Xue W, Zuber J, et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell. 2008;135(5):852–864. .
  • Li Y, Fu L, Li JB, et al. Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma. Gastroenterology. 2014;146(7):1701–1713.
  • Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003;63(15):4561–4567.
  • Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–954.
  • Bristow JM, Reno TA, Jo M, et al. Dynamic phosphorylation of tyrosine 665 in pseudopodium-enriched atypical kinase 1 (PEAK1) is essential for the regulation of cell migration and focal adhesion turnover. J Biol Chem. 2013;288(1):123–131.
  • Ding C, Tang W, Fan X, et al. Overexpression of PEAK1 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer through modulating ERK1/2 and JAK2 signaling. Cell Death Dis. 2018;9(8):802–809.
  • Huang L, Wen C, Yang X, et al. PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d. Cell Death Dis. 2018;9(3):271–278.
  • Strnadel J, Choi S, Fujimura K. eIF5A-PEAK1 signaling regulates YAP1/TAZ protein expression and pancreatic cancer cell growth. Cancer Res. 2017;77(8):1997–2007.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.